Biotech

All Articles

A closer take a look at Strong Biotech's Ferocious 15

.In this particular full week's episode of "The Best Line," we're diving into Strong Biotech's annua...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is still soaring from Eli Lilly's event celebrating the commendation of Alzheimer's co...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and...

Lykos will ask FDA to reconsider its own decision observing turndown of MDMA therapy for post-traumatic stress disorder

.Observing a bad presenting for Lykos Therapeutics' MDMA candidate for trauma at a latest FDA adviso...

AN 2 halves census, quits stage 3 trial after data dissatisfy

.AN2 Rehabs is actually reviewing its organization in feedback to poor midphase data, promising to g...

Merck spends $700M for bispecific, spying autoimmune opening and chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 million upfront to test Amgen in a blood cancer market. The ...

Gilead spends J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences about to an FDA decision for its liver ailment medicine seladelpar, the busine...

' All palms on deck' at Lilly as peers target weight problems market

.CEO David Ricks may find the providers putting together camping tents at basecamp responsible for E...

Entero giving up staff, moving out of workplace and also stopping briefly R&ampD

.Mattress Liquidators has turned Entero Rehabs white as a slab. The lender bought Entero to settle i...

Exelixis goes down ADC after deciding it is actually no match for Tivdak

.Exelixis is actually surrendering on its own tissue factor (TF)- targeting antibody-drug conjugate ...